Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Total Debt (2016 - 2025)

Guided Therapeutics' Total Debt history spans 14 years, with the latest figure at $60000.0 for Q4 2025.

  • On a quarterly basis, Total Debt fell 63.64% to $60000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $60000.0, a 63.64% decrease, with the full-year FY2025 number at $60000.0, down 63.64% from a year prior.
  • Total Debt hit $60000.0 in Q4 2025 for Guided Therapeutics, down from $108000.0 in the prior quarter.
  • Over the last five years, Total Debt for GTHP hit a ceiling of $1.2 million in Q2 2024 and a floor of $32000.0 in Q3 2022.
  • Historically, Total Debt has averaged $360800.0 across 4 years, with a median of $110000.0 in 2021.
  • Biggest five-year swings in Total Debt: surged 1674.0% in 2021 and later tumbled 94.7% in 2022.
  • Tracing GTHP's Total Debt over 4 years: stood at $110000.0 in 2021, then fell by 9.09% to $100000.0 in 2022, then surged by 65.0% to $165000.0 in 2024, then crashed by 63.64% to $60000.0 in 2025.
  • Business Quant data shows Total Debt for GTHP at $60000.0 in Q4 2025, $108000.0 in Q3 2025, and $95000.0 in Q2 2025.